


57. Hamdy N, Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. *Toxicol Appl Pharmacol* 2012; 261: 292–299.
58. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; 292: 2227–2236.
59. Lo GH, Chen WC, Wang HM, et al. Randomized controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. *J Gastroenterol Hepatol* 2012; 27: 1681–1687.
60. Vlachogiannakos J, Goulis J, Patch D, et al. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. *Aliment Pharmacol Ther* 2000; 14: 851–860.
61. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. *N Engl J Med* 2005; 353: 2254–2261.
62. Imperiale T, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. *Hepatology* 2001; 33: 802–807.
63. Grace N, Lo GH, Nevens F, et al. Preventing rebleeding in 2010. In: De Franchis R et al. *Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop*, 5th Edition. Wiley-Blackwell press. London 2004: 121–131.
64. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. *Hepatology* 2004; 40: 793–801.
65. Garcia-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. *N Engl J Med* 2010; 362: 2370–2379.
66. Garcia-Pagán JC, Di Pascoli M, Caca K et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. *J Hepatol*. 2013; 58: 45–50.
67. Lo GH, Lai KW, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomised trial. *Hepatology* 2000; 32: 462–465.
68. De la Pena J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol compared with ligation for prophylaxis for prophylaxis of variceal rebleeding: a multicenter trial. *Hepatology* 2005; 41: 572–578.
69. Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. *J Hepatol* 2011; 55: 794–799.
70. Sersté T, Melot C, Francoz C, et al. Deleterious effect of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology* 2010; 52: 1017–1022.
71. Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effect of beta-blockers improve survival of patients with cirrhosis during a window in the disease. *Gut* 2012; 61: 967–969.
72. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. *J Hepatol* 2014; 60: 643–653.
73. Garcia-Tsao J, et al. AASLD Practice Guidelines. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. *Hepatology* 2007; 46: 922–938.
74. Ryan BM, Stockbrugger RW, Ryan JM. A Pathophysiologic, Gastroenterologic and radiologic Approach to the Management of gastric Varices. *Gastroenterology* 2004; 126: 1175–1189.
75. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. *Hepatology* 1992; 16: 1343–1349.
76. Sarin SK, Kumar A. Gastric varices: profile, classification and management. *Am J Gastroenterol* 1989; 84: 1244–1249.
77. Lo Gh, Lai Kh, Cheng JS, et al. A prospective randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. *Hepatology* 2001; 33: 1060–1064.
78. Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal haemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. *Hepatology* 2006; 43: 690–697.
79. Tripathi D, Therapondos G, Jackson E, et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clinical and haemodynamic correlations. *Gut* 2002; 51: 270–274.

Víte, že listovačky časopisu Klinická farmakologie a farmacie jsou volně dostupné on-line?



V posledních číslech
najdete tato
hlavní témata:

- Farmakoterapie v zubním lékařství (1/2020)
- Farmakoterapie v těhotenství a při kojení (4/2019)
- Nežádoucí účinky léčiv (3/2019)

... a mnoho článků z jiných oblastí medicíny a farmacie

www.klinickafarmakologie.cz



Mohou být přínosné i pro vás...